Abstract | ATP-sensitive potassium channels (K ATP channels) link cell metabolism to electrical activity by controlling the cell membrane potential. They participate in many physiological processes but have a particularly important role in systemic glucose homeostasis by regulating hormone secretion from pancreatic islet cells. Glucose-induced closure of K ATP channels is crucial for insulin secretion. Emerging data suggest that K ATP channels also play a key part in glucagon secretion, although precisely how they do so remains controversial. This Review highlights the role of K ATP channels in insulin and glucagon secretion. We discuss how K ATP channels might contribute not only to the initiation of insulin release but also to the graded stimulation of insulin secretion that occurs with increasing glucose concentrations. The various hypotheses concerning the role of K ATP channels in glucagon release are also reviewed. Furthermore, we illustrate how mutations in K ATP channel genes can cause hyposecretion or hypersecretion of insulin, as in neonatal diabetes mellitus and congenital hyperinsulinism, and how defective metabolic regulation of the channel may underlie the hypoinsulinaemia and the hyperglucagonaemia that characterize type 2 diabetes mellitus. Finally, we outline how sulphonylureas, which inhibit K ATP channels, stimulate insulin secretion in patients with neonatal diabetes mellitus or type 2 diabetes mellitus, and suggest their potential use to target the glucagon secretory defects found in diabetes mellitus.
Introduction
Whether you indulge in a large slice of chocolate cake or decide to fast for the day, the pancreatic islets of Langerhans ensure that the swings in your blood sugar level are not large. Each islet contains several types of endocrine cells, which have opposing roles in glucose homeostasis. Insulin, the only hormone to lower blood glucose concentration, is secreted by the β cells, which make up >60% of the islet: it stimulates glucose uptake and storage in liver, muscle and adipose tissue. Insufficient insulin secretion results in elevated blood glucose levels, a hallmark of diabetes mellitus. The α cells release gluca gon, the body's principal plasma-glucose-elevating hormone. By increasing hepatic glucose production, gluca gon pre vents hypoglycaemia during fasting and exercise and provides glucose to the brain and active muscles. Somatostatin, released from δ cells, inhibits both insulin and glucagon secretion.
Hormone secretion from all three cell types is triggered by action potential firing. This leads to the influx of calcium ions (Ca 2+ ) through voltage-gated Ca 2+ channels and a rise in the intracellular Ca 2+ concentration that activates secretory granule exocytosis. In β cells and δ cells, glucose metabolism elicits electrical activity and hor mone secretion by closing ATP-sensitive potassium channels (K ATP channels). [1] [2] [3] [4] Paradoxically, K ATP channel closure seems to have the opposite effect in α cells, where genetic or pharmacological inactivation of the channel is associated with inhibition of secretion. 5, 6 This Review provides an introduction to the differing role of K ATP channels in insulin and glucagon secretion and considers how defective K ATP channel activity causes the hormonal abnormalities associated with diseases such as diabetes mellitus and hyperinsulinism.
Regulation of electrical activity
The K ATP channel consists of four pore-forming Kir6.x subunits and four regulatory sulphonylurea receptor (SUR) subunits, 2 which in islet cells constitute Kir6.2 (encoded by KCNJ11) and SUR1 (encoded by ABCC8). [7] [8] [9] The hallmark of the K ATP channel is its inhibition by intracellular ATP, which binds to Kir6.2 to cause channel closure. 10 Conversely, interaction of intracellular MgATP and MgADP with SUR1 stimulates channel opening. [11] [12] [13] Modulation by adenine nucleotides means that K ATP channel activity is, in turn, regulated by cell metabolism. The fact that magnesium ions (Mg 2+ ) are not required for ATP (or ADP) binding to Kir6.2 but are needed for binding to SUR1 reflects the different structure of the nucleotide binding sites on these proteins; this property can also be used experimentally to distinguish between nucleotide effects on Kir6.2 and SUR1. Drug binding to SUR1 also regulates channel activity: K ATP channel openers, such as diaz oxide, stimulate channel opening whereas sulphonylurea drugs, such as tolbutamide and glibenclamide, induce channel closure.
K ATP channels link metabolism to cellular electrical activity by regulating the membrane potential. Gating of the K ATP channel is both voltage-independent and timeindependent, so that K ATP channel activity results in an ATP-gated leak current. 17 The effect of this leak current on the electrical activity of the cell depends on the relative magnitudes of the K ATP current and other membrane currents. When the K ATP current dominates, the membrane will hyperpolarize, switching off electrical activity. Conversely, if inward currents dominate-as is often the case when K ATP channels are almost completely closedmembrane depolarization occurs. If this depolarization is sufficient, electrical activity will be initiated. 18 It is important to recognize that when the electrical resistance of the membrane is very high-as when most K ATP channels are shut-even a tiny change in current can have a large effect on the membrane potential.
Role of the K ATP channel in β cells
The K ATP channel is essential for glucose-stimulated insulin secretion. 1 At glucose concentrations that do not stimulate insulin secretion, the ambient level of intracellular ATP ensures that K ATP channel activity is high enough to keep the membrane hyperpolarized, preventing electrical activity and insulin secretion (Figure 1 ). K ATP channel closure in response to metabolically generated ATP reduces the K ATP current so that background inward currents now make a greater contribution to the membrane potential. As a consequence, the membrane depolarizes and electrical activity is initiated if this depolariza tion exceeds the threshold for initiation of action potential firing-which in β cells lies between -60 mV and -50 mV. 19 Voltage-gated Ca 2+ channels activate during the action potentials, and the associated Ca 2+ influx triggers Ca 2+ -dependent exocytosis of insulin granules. L-type Ca 2+ channels underlie the action potential in rodent β cells, 20 but in humans P/Q-type Ca 2+ channels are functionally more important. 21 Unlike mouse β cells, human β cells also have a prominent T-type Ca 2+ current that activates at voltages as negative as -60 mV and a voltage-gated Na + current. 21 These differences, together with the smaller K ATP current (10% of that in mouse β cells), may explain why electrical activity and insulin secretion from human β cells are triggered at lower glucose concentrations than in mouse β cells. 22 At glucose concentrations between ~6 mM and 20 mM, electrical activity in mouse β cells consists of characteristic bursts of action potentials (lasting 5-15 s), which are super imposed on depolarized plateaux and separated by repolarized electrically silent intervals (5-20 s), 23, 24 as shown schematically in Figure 1 . The duration of the bursts increases, and the interburst interval decreases, with increasing glucose concentration and eventually culminates in continuous electrical activity. β cells from other species also generate bursts, but these are less regular than those seen in the mouse, and different ion channels probably contribute to their generation. Although the bursts were first described ~45 years ago, [25] [26] [27] [28] their origin still remains a matter of debate. Thus, they have variously been attributed to oscillations in K ATP channel activity,
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Key points ■ Closure of ATP-sensitive potassium channels (K ATP channels) stimulates insulin secretion but inhibits glucagon release ■ The role of K ATP channels in insulin secretion is well understood, but precisely how glucose inhibits glucagon release remains controversial ■ Activating mutations in K ATP channel genes cause neonatal diabetes mellitus, whereas loss-of-function mutations cause congenital hyperinsulinism ■ Both insufficient insulin secretion and dysregulation of glucagon release contribute to impaired glucose homeostasis in type 2 diabetes mellitus (T2DM) ■ A common K ATP channel haplotype predisposes to T2DM ■ An age-dependent decline in metabolism may also contribute to T2DM via mechanisms that are both dependent on, and independent of, K ATP channels opening of small-conductance Ca 2+ -activated K + channels, 31 periodic activation of depolarizing currents, 32 Ca 2+ channel inactivation 33 or cell-cell coupling. 19, 34 Many of the early patch-clamp studies of β cells were performed on isolated cells maintained in tissue culture, which lack the rapid oscillatory electrical activity characteristic of β cells in freshly isolated intact islets. 23 Instead, electrical activity is either continuous, or bursting occurs on a timescale 10-20 times slower than that in intact islets. 31, 35 This finding suggests that β-cell isolation could lead to changes in channel density, channel regulation and/or cell-cell coupling. When the integrity of the islet is maintained, and electrical activity is recorded from β cells lying within the islet, normal bursting activity is recorded (Figure 1c) . The various patch-clamp configurations, and how they can be used to study ion channel function, are illustrated in Figure 2 .
Perforated patch measurements (which preserve cellular metabolism, Figure 2e ) from β cells within intact islets reveal that each glucose-induced burst is associ ated with the gradual development of an outward current (termed K slow ), 36, 37 which is produced by activation of Ca 2+ -activated K + channels (50%) and reactivation of K ATP channels (50% -activated K + -channels and K ATP channels. As a result, the membrane depolarizes, tr iggering a second burst. 19 The progressive lengthening of the bursts observed as glucose levels increase results from the reduced activation of K ATP channels during electrical activity. This decline in K ATP channel activity has been attributed to increased ATP generation (as a result of increased glucose metabolism), which enables more efficient buffer ing of ATP consumption by Ca 2+ -ATPases and further elevates the sub membrane ATP concentration. 19 Thus, K ATP channel closure not only initiates electrical activity, but oscillations in the reactivation and closure of K ATP channels shape the bursting behaviour of the β cell and underlie the graded increase in insulin secretion observed as glucose levels are elevated. This model also explains how sulphonylureas, which close K ATP channels, convert oscillatory electrical activity into continuous action potential firing. 41 Sulphonylureas have been used for almost 60 years to treat type 2 diabetes mellitus (T2DM) because of their ability to close K ATP channels and stimulate electrical activity and insulin secretion. 15, 42 These drugs act as partial antagonists, producing a maximum block of only ~60% if studied in excised membrane patches (Figure 2b ) in the absence of intracellular Mg-nucleotides. 43 However, when studied under conditions where intracellular nucleotides are present, sulphonylureas fully block channel activity. 14 This is because sulphonylureas suppress the stimulatory effects of Mg-nucleotides but do not affect inhibition of the channel by ATP (or ADP). Consequently, nucleotide block is enhanced (as it is no longer antagonized by Mg-nucleotide activation) and this inhibition adds to that of the sulphonylurea. 44, 45 This complicated mechanism of drug action has an important consequence: it predicts that mutations that substantially decrease ATP inhibition will also reduce the maximal extent of sulphonylurea block of the whole-cell K ATP current. It may also explain why some patients with severe activating K ATP channel mutations (see below) cannot be treated with sulphonylureas. 46 
Role of the K ATP channel in α cells
Glucagon is released from α cells in response to a fall in the blood glucose concentration or an increase in circulating levels of amino acids, fatty acids, hormones and neurotransmitters. 47, 48 Precisely how glucose regulates glucagon release remains controversial. At the heart of the debate is whether secretion is primarily controlled by an intrinsic mechanism (as in the β cell), or by an extrinsic mechanism that involves paracrine factors (such as hormones, metabolites and ions) released from neighbouring β cells or δ cells in response to changes in plasma glucose levels, 47 or even from innervating nerve terminals. 49 These hypotheses are not, of course, mutually exclusive. Furthermore, whatever mechanism(s) are involved, studies on islets from mice lacking K ATP channels indicate that K ATP channels have a key role. 5, 6, 50 What is in question is whether regulation of K ATP channel activity directly controls glucagon secretion (as it does insulin release) or if channel activity has an indirect, permissive role by setting the stage for other mechanisms that operate via changes in membrane conductance.
Candidates for a glucose-dependent extrinsic regulator of glucagon release include insulin, 51 zinc 52 and GABA, 53 all of which are released from β cells when blood glucose levels rise and have been shown to inhibit α-cell electrical activity and glucagon secretion in isolated islets. 54 Zinc, an activator of K ATP channels, 55 co-crystallizes with insulin and is co-released in response to glucose. However, it seems that zinc is not a physiological regulator of glucagon release, because mice lacking zinc in their insulin granules (owing to a β-cell-specific knockout of the zinc transporter ZnT8) show no defect in gluca gon secretion. 56 Somatostatin, released from δ cells in response to glucose elevation, may also contribute to the inhibitory action of glucose on glucagon secretion, as glucagon secretion in islets isolated from mice lacking somatostatin is enhanced and no longer regulated by glucose. 57, 58 Nevertheless, it remains possible that lack of somatostatin, or indeed ZnT8, may lead to compensatory changes that mask the normal physiological function of these proteins.
The fact that in both human and rodent islets, glucagon secretion is maximally inhibited by glucose concentrations with no or little stimulatory effect on insulin secretion 59 and that glucose remains capable of inhibiting glucagon secretion in isolated islets (that is, when innervation has been severed) 60 suggests that α cells do indeed possess an intrinsic glucose-sensing mechanism. The nature of this regulation remains obscure, but modulation of α-cell electric al activity is an obvious candidate.
Unlike β cells, α cells are electrically active in the absence of glucose (Figure 3) . [61] [62] [63] [64] This difference reflects the fact that the whole-cell K ATP conductance measured in metabolically intact α cells exposed to glucose-free solution is much less than that in β cells (1-10%) . 65, 66 However, the maximal K ATP conductance (measured in the absence of intracellular ATP) is as high, or higher, in α cells than in β cells. 67, 68 The half-maximal concentration of MgATP required to inhibit the K ATP current in β cells dialysed with MgATP is much higher (about sevenfold) than that observed in inside-out patches, 69 probably due to intracellular generation of MgADP. Interestingly, it requires less ATP to block whole-cell K ATP currents in α cells than in β cells, 70 which may account for the smaller K ATP currents observed in metabolically intact α cells than in β cells.
Whatever the reason that the K ATP conductance in α cells exposed to low glucose concentrations is less than that in β cells, it ensures that the membrane is sufficiently depolarized for action potential firing to occur in the absence of glucose. The paradox is why further closure of K ATP channels should reduce glucagon secretion but increase insulin release: surprisingly, the sulphonylurea tolbutamide inhibits glucagon secretion yet activates insulin release. 60 Tolbutamide also results in α-cell membrane depolarization, a reduction in the peak amplitude of the action potential and, in some cases, even cessation of electrical activity. Our group have postulated that depolarization results in voltage-dependent inactivation of inward currentsmost importantly sodium currentsinvolved in action potential firing. 60, 71 This idea is supported by the fact that the Na + -channel blocker tetrodotoxin, which mimics the effect of tolbutamide on peak action potential amplitude, also inhibits glucagon release. Importantly, the reduction in action potential amplitude is expected to reduce Ca 2+ entry through P/Qtype Ca 2+ channels and thereby decrease glucagon release. From the voltage-dependence of exocytosis, it can be predicted that a 10-15 mV reduction in action potential peak voltage will produce a ~80% decrease in exocytosis. 72 A key question is whether glucose exerts a tolbutamidelike effect on K ATP channel activity and action potential firing. The fact that glucose inhibition of gluca gon secretion is antagonized by low concentrations of diazoxide suggests this may be the case. 60 Indeed, a small (10%) glucose-induced reduction in K ATP channel activity has been observed in isolated rat α cells. 73 Puzzlingly, in stark contrast to what is observed in intact islets, glucose stimulates electrical activity and secretion in isolated α cells. This difference may be because the whole-cell K ATP conductance is greater in isolated α cells (0.45 nS/pF) 73 than in α cells within intact islets (0.02 nS/pF; P. Rorsman, unpublished work). A possible explanation for this difference is that the loss of surrounding β cells may induce changes in α-cell gene expression, as was observed fo llowing β-cell destruction. A novel mechanism for extrinsic regulation of glucagon release has been proposed by Li et al. based on the finding that γ-hydroxybutyrate (GHB) is released from β cells in response to glucose metabolism and that GHB release is required for glucose-induced inhibition of glucagon release. 75 Both the α-cell receptor for GHB and the molecular mechanism by which GHB prevents glucagon secretion are unknown, but an intriguing possibility is that GHB blocks K ATP channels, either directly or indirectly.
Role of the K ATP channel in exocytosis
Both Kir6.2 and SUR1 are found at high density in densecore secretory granules of pancreatic β cells, α cells and δ cells [76] [77] [78] [79] but their role there is unclear and the type of dense-core granule involved is controversial. Several studies have provided evidence that SUR1 and Kir6.2 localize to the insulin secretory granules in β-cells. [76] [77] [78] How ever, others have argued that K ATP channel subunits are confined to non-insulin-containing dense-core granules. 79 Why K ATP channels are present in the granules is also unknown. Possibly, it might provide a route for trafficking K ATP channels to or from the plasma membrane. Evidence also exists that K ATP channels have a role in exocytosis. This idea is suggested by the fact that SUR1 binds to the e xocytosis-regulating protein EPAC2.
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EPAC2 mediates the incretin effects of hormones such as glucagon-like peptide 1 (GLP-1), and these effects are absent or reduced in mice lacking SUR1. 81, 82 One hypothesis suggests that by enhancing the ATP-sensitivity of K ATP channels, EPAC2 facilitates K ATP channel closure and membrane depolarization in response to incretins (such as GLP-1). 83 Another idea is that SUR1 serves as a scaffold protein for EPAC2 and other proteins involved in exocytosis. Interactions of SUR1 with various exocytotic proteins, such as syntaxin-1A 84 and the Ca 2+ sensor piccolo 80 have also been reported but their functional significance is not yet established.
In addition to the well-documented ability of sulphonylureas to close K ATP channels (and so trigger islet-cell secretion), these drugs potentiate Ca 2+ -evoked exo cytosis in both β cells 85 and α cells 86 by a mechanism that is downstream of K ATP channel closure. However, K ATP channels are not involved, as sulphonylureas still stimulate exo cytosis in β cells from mice lacking SUR1. 81 Although these findings have been contested, 87 it has been dis covered in the past few years that sulphonylureas bind directly to EPAC2. 88 The extent to which this mechanism of drug action is of therapeutic significance remains unclear and, in any case, it is dependent on sulphonylurea-induced membrane depolarization and Ca 2+ entry.
Effects of K ATP channel mutations
Neonatal diabetes mellitus Gain-of-function mutations in the genes encoding either Kir6.2 (KCNJ11) or SUR1 (ABCC8) cause neonatal diabetes mellitus (NDM), a rare monogenic form of diabetes mellitus that usually presents within the first 6-9 months of life. [89] [90] [91] [92] The disease may be permanent or follow a remitting-relapsing time course. The reduced insulin secretion causes not only diabetes mellitus but also intrauterine growth retardation and a low birth weight. Because K ATP channels are expressed in multiple tissues, around 20% of patients also exhibit neurological symptoms, such as mental and motor developmental delay, muscle hypo tonia, hyperactivity and, in rare cases, epilepsy. 90 Expression of a human NDM mutation (Kir6.2-Val59Met) in mice indicates that hypotonia results from impaired neuronal regulation of muscles, not from enhanced K ATP channel activity in skeletal muscle. 93 Multiple mutations in Kir6.2 and SUR1 that cause NDM have been studied biophysically. 46, [94] [95] [96] [97] [98] All increase the K ATP current, either by reducing the ability of ATP to block the channel or by enhancing Mg-nucleotide stimulation. Figure 3 | K ATP channel modulation of α-cell electrical activity. a | Glucagon secretion is stimulated at low glucose levels and b | inhibited at high glucose levels. c | Schematic illustrating the changes in membrane potential (V), whole-cell K ATP current (K ATP channel activity) and glucagon secretion produced by increasing glucose levels from 1 mM to 6 mM or by hyperactivation of the K ATP channel using the K ATP -channel activator diazoxide (far left). K ATP channels are under strong tonic inhibition (99%) at low glucose levels, so that the membrane is depolarized sufficiently to elicit electrical activity, which consists of large-amplitude action potentials. Electrical activity is associated with activation of voltage-gated Na + channels and voltage-gated Ca 2+ channels, and Ca 2+ influx through the latter triggers glucagon secretion. Increasing glucose levels to 6 mM closes K ATP channels completely, further depolarizing the membrane. As in β cells, membrane depolarization increases action potential frequency. However, it also reduces α-cell spike amplitude, due to inactivation of voltage-gated Na + channels, which leads to less activation of the P/Q-type Ca 2+ channels linked to exocytosis and thus to reduced glucagon secretion. Thus, both increased (diazoxide) and reduced (high glucose) K ATP channel activity inhibit glucagon secretion but by different mechanisms-membrane hyperpolarization and reduced spike height, respectively. Abbreviation: K ATP channels, ATP-sensitive potassium channels.
The increased K ATP current prevents β-cell depolarization in response to glucose metabolism and impairs insulin secretion. Mice in which activating K ATP channel mutations are expressed specifically in the β cell show severe loss of glucose-induced insulin secretion and diabetes mellitus. [99] [100] [101] However, sulphonylureas, which close the open K ATP channels, remain effective secretagogues. In general, those mutations that produce the greatest reduction in ATP sensitivity are associated with the most severe clinical phenotype. 95 The effect of activating Kir6.2 and SUR1 mutations on glucagon secretion has received less attention. Nevertheless, one might predict that the effect would resemble that of diazoxide; 60 in other words, severe mutations that cause a large increase in K ATP conductance would be expected to inhibit glucagon secretion whereas those that produce a small increase in K ATP current would stimulate glucagon release (Figure 4b,d) .
Prior to the discovery that K ATP channel mutations could cause NDM, all patients with NDM were treated with insulin. Now, >90% of patients with NDM have switched to sulphonylurea therapy, 102, 103 which substantially improves their glucose homeostasis and reduces the risk of diabetic complications. 102, 104 Interestingly, patients with NDM usually require a much higher sulphonylurea dose (relative to body weight) than patients with T2DM. A lower sensitivity of the mutant K ATP channel to sulphonylureas, 46, 99 or a higher open probability at ambient glucose levels, may contribute to the need for a higher dose. The sulphonylurea dose required also often declines with time after the onset of therapy, which suggests that β-cell mass or function may gradually improve when glucose homeostasis and/or normal K ATP channel activity is restored. Fascinatingly, in a subset of mice expressing a β-cell-specific activating K ATP channel mutation, early sulphonylurea treatment led to permanent remission of diabetes mellitus. 105 To what extent this might be the case in humans is unknown. Sulphonylurea therapy might also restore normal function of glucagon-secreting α cells by bringing the K ATP -channel activity in α cells into a range in which paracrine factors and circulating hormones become operational.
Congenital hyperinsulinism
Loss-of-function mutations in Kir6.2 or SUR1 result in congenital hyperinsulinism (HI), which is characterized by persistent and unregulated insulin secretion despite low blood glucose levels. 92, [106] [107] [108] [109] The disease usually presents soon after birth as life-threatening hypoglycaemia. Strong suppression of glucagon secretion and of counter-regulation during hypoglycaemia also occur. 110 Histologically, HI may be diffuse or focal. In diffuse HI, β cells in all islets are affected, whereas in focal HI, affected islets are confined to a small region of the pancreas. Focal HI usually occurs when the patient carries a recessive mutation in the paternal allele and locally loses the (normal) maternal allele by somatic deletion. Focal HI is treated by identification of the affected region of the pancreas using 18 F-dihydroxyphenylalanine PET ( 18 F-DOPA PET) scanning, followed by its surgical excision, and this treatment results in a cure. 111, 112 Diffuse HI is usually inherited recessively, but dominant mutations, which cause a less severe phenotype, have also been identified. 108 The disease is sometimes treatable by K ATP channel openers, such as diazoxide, but most cases require near total pancreatectomy. Interestingly, patients with dominant HI who do not undergo pancreatectomy may develop diabetes mellitus in later life. 108, 109 Patch-clamp studies have shown that β cells obtained from resected pancreases of patients with congenital HI have few or no functional K ATP channels, 113 This may be due to lack of K ATP channels in the plasma membrane (due to impaired protein expression, maturation, assembly or trafficking) or to loss of Mg-nucleotide activation. The resulting reduction in K ATP channel activity explains why β cells are depolarized and show increased intra cellular calcium and insulin secretion, even at low glucose levels. Glucose elevation is able to cause a further modest Hyperglycaemia decreases K ATP channel activity and inhibits glucagon secretion. Hypoglycaemia increases K ATP channel activity and stimulates glucagon release. c | In β cells from patients with type 2 diabetes mellitus (T2DM), K ATP channel activity is enhanced (either because of impaired metabolism or activating K ATP channel variants or mutations). Hypoglycaemia suppresses insulin secretion further. Hyperglycaemia increases insulin secretion but not as much as in nondiabetic β cells. 140 Closure of K ATP channels by sulphonylureas (SU) reduces channel activity at normal glycaemic levels and so boosts insulin secretion in both normoglycaemia and hypoglycaemia. The pink circle shows that in neonatal diabetes mellitus (NDM) K ATP channel activity is so much enhanced that insulin secretion is abolished. The brown circle shows that in congenital hyperinsulinism (HI) there is little or no K ATP channel activity, which causes persistent insulin secretion. d | In α cells from patients with T2DM, K ATP channel activity is enhanced. Because of the bell-shaped relationship, reduced K ATP channel activity in response to hyperglycaemia leads to increased glucagon secretion whereas hypoglycaemia causes reduced glucagon secretion. The brown circle illustrates the situation in severe HI and the pink circle in NDM. Abbreviation: K ATP channels, ATP-sensitive potassium channels.
increase in insulin secretion, 114 presumably via its effect on metabolic amplifying pathways that lie downstream of K ATP channel closure. 115 A major puzzle in studies of congenital HI is why mouse models do not recapitulate the human disease, even when the identical mutation is involved. 116 In mice, genetic deletion of Kir6.2 or SUR1 does not cause sustained hypoglycaemia-rather, blood glucose levels normalize within a few days of birth, and in later life animals develop glucose intolerance. 117, 118 In addition, whereas heterozygous Kir6.2 and SUR1 knockout mice do show mild HI and improved glucose tolerance, 119 except for a few rare dominant mutations in humans, most people with heterozygous mutations are nonsymptomatic. Why these differences occur is still unclear.
Insulin secretion from islets isolated from patients with congenital HI and mice lacking SUR1 also shows some differences. 114 A further complication is that freshly isolated islets from mice lacking SUR1 behave differently from those that have been cultured overnight. 120 It is also important to remember that mouse and human islets are not identical. In contrast to human islets, mouse islets are densely innervated. 121 Furthermore, adrenaline stimulates glucagon secretion (by binding to β-receptors 122 ) in mouse islets, but (if anything) inhibits glucagon secretion in human islets. 59 As a consequence of these differences, the counter-regulatory response is much weaker in humans than in mice, which might contribute to the differences in mice and humans with HI.
Role of the K ATP channel in T2DM
T2DM is far more prevalent than NDM and a worldwide scourge. It currently afflicts 335 million people and the number increases hourly.
1 T2DM is a bihormonal disorder that involves both insufficient insulin secretion and defective glucagon secretion. Glucagon secretion is increased at high plasma glucose concentrations (exacerbating the consequences of impaired insulin secretion) and is inadequate at low plasma glucose levels (potentially resulting in fatal hypoglycaemia). 123 Oversecretion of glucagon contributes considerably to the hyperglycaemia in patients with T2DM, and suppression of glucagon secretion by admini stration of somatostatin leads to a marked reduction in the insulin required to maintain euglycaemia. 124 The report that mice in which the gluca gon receptor has been genetically inactivated remain normoglycaemic even after complete chemical destruction of the β cells, whereas wild-type mice become strongly hyperglycaemic, highlights the role of glucagon as a causal factor in diabetic hyper glycaemia. 125 Interestingly, both under physiological and diabetic conditions, very few α cells (only ~2%) are needed to prevent major counter-regulatory deregulation.
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T2DM has a strong genetic component, but disease risk is also enhanced by factors such as age, pregnancy and obesity. 1 Multiple genes are probably involved, which may differ between individuals. One of the first to be associated with increased T2DM risk was a common polymorphism (Glu23Lys) in the gene encoding Kir6.2 (KCNJ11). 127, 128 Subsequently, this variant was shown to be in strong linkage disequilibrium with another variant, Ser1369Ala, in the adjacent ABCC8 gene that encodes SUR1, such that >95% of people who are homomeric for Kir6.2-Lys23 also carry two copies of SUR1-Ala1369. Thus, either variant could cause the increased disease risk. Although the increase in individual risk is small (OR 1.2), the population risk is highly significant, because 58% of people carry at least one Kir6.2-Lys23 allele. 128 How the 'at-risk' variant(s) predisposes to T2DM is not fully resolved. In clinical studies, the Kir6.2-Lys23 variant has been shown to reduce glucose-induced suppression of glucagon secretion whilst not affecting insulin secretion. 129 At the molecular level, the effects of the mutation(s) on K ATP channel function are subtle and vary between laboratories. For example, increases, decreases and no change in ATP sensitivity have been documented for the Kir6.2-Lys23 variant. [130] [131] [132] Studies combining both polymorphisms reveal that the Kir6.2-Lys23/ SUR1-Ala1369 variant shows a very small reduction in the ATP concentration causing half-maximal inhibition (IC 50 ) of K ATP channel activity. 133 This may be because the SUR1-Ala1369 variant enhances the ATPase activity of nucleotide binding site 2 of SUR1 and leads to increased nucleotide activation of the channel by Mg-nucleotides. 134 However, although there is a difference in IC 50 , at higher (presumably more physiological) ATP concentrations no difference in channel inhibition exists between 'low-risk' and 'at-risk' channels. 134 Thus, how the Kir6.2-Lys23/ SUR1-AlaA1369 variant increases the risk of T2DM is not immediately clear.
A further complication is that T2DM is (usually) a disease of later life. This fact is generally attributed to a gradual decline in β-cell function or mass, which is postulated to occur with age in all individuals but only progresses to overt T2DM in people who initially have compromised β-cell function. Clinical evidence indeed suggests a progressive age-dependent decline in β-cell function. 135 Although longitudinal studies on isolated human islets are impossible (for obvious reasons), evidence exists that islets from organ donors with T2DM exhibit reduced glucose metabolism and glucose-induced insulin secretion. 136 Fascinatingly, restoration of glucose metabolism by pharmacological activators of gluco kinase restores glucose metabolism and insulin secretion in these islets. 136 Thus, impaired glucose metabolism may be a feature of T2DM. If so, this would decrease glucoseinduced K ATP channel closure and, particularly if combined with a lower K ATP channel ATP sensitivity, might compromise β-cell function. Importantly, even small changes in K ATP channel activity can have dramatic effects on β-cell and α-cell electrical activity.
Sulphonylureas, by closing K ATP channels, are expected to normalize Ca 2+ entry in β cells from patients with T2DM. However, if a metabolic defect exists, sulphonyureas will not fully restore insulin secretion because glucose metabolites are also required for downstream steps in insulin release (subsequent to K ATP channel closure). By contrast, metabolism is not predicted to be impaired in patients with NDM caused by K ATP channel mutations. This difference may explain why sulphonylureas continue to work in NDM, but-despite being initially effective -eventually fail in T2DM (secondary failure). 137 
Conclusions
K ATP channel closure has a dual role in the regulation of pancreatic hormone release. Depending on the relative magnitudes of the resting K ATP current and other currents in the cell, it can either stimulate (insulin) or inhibit (glucagon) secretion. Dysregulation of this mechanism might underlie the reciprocal changes in insulin secretion and glucagon secretion found in T2DM. Gain-of-function mutations cause a spectrum of diabetes syndromes that range in severity from NDM to T2DM; conversely, loss-of-function mutations cause HI. Defects in islet cell metabolism may also be expected to affect glucose homeostasis via changes in K ATP channel activity, and several studies suggest that it may contribute to impaired hormone secretion in both NDM 138, 139 and T2DM. Future work should be directed at investigating the role of impaired K ATP channel regulation in T2DM, and its effect on both insulin and glucagon secretion. Available data also suggest it might be worth exploring the potential of sulphonylureas for the treatment of the impaired glucagon secretion found in both type 1 diabetes mellitus and T2DM.
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